ES2184808T3 - TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMELINIZING STATES USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE, THYROSINE OR TRIPTOPHAN AND OPTIONALLY A VITAMIN B12 COMPOSITE. - Google Patents

TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMELINIZING STATES USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE, THYROSINE OR TRIPTOPHAN AND OPTIONALLY A VITAMIN B12 COMPOSITE.

Info

Publication number
ES2184808T3
ES2184808T3 ES95933488T ES95933488T ES2184808T3 ES 2184808 T3 ES2184808 T3 ES 2184808T3 ES 95933488 T ES95933488 T ES 95933488T ES 95933488 T ES95933488 T ES 95933488T ES 2184808 T3 ES2184808 T3 ES 2184808T3
Authority
ES
Spain
Prior art keywords
phenylalanine
combination
multiple sclerosis
demelinizing
triptophan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933488T
Other languages
Spanish (es)
Inventor
Cari Loder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420116A external-priority patent/GB9420116D0/en
Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2184808T3 publication Critical patent/ES2184808T3/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)
  • Fodder In General (AREA)

Abstract

Method for treating multiple sclerosis or encephalomyelitis by administering to a patient a combination of a tricyclic antidepressant drug and tyrosine or phenylalanine or both.
ES95933488T 1994-10-05 1995-10-05 TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMELINIZING STATES USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE, THYROSINE OR TRIPTOPHAN AND OPTIONALLY A VITAMIN B12 COMPOSITE. Expired - Lifetime ES2184808T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en) 1995-04-26 1995-04-26 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product

Publications (1)

Publication Number Publication Date
ES2184808T3 true ES2184808T3 (en) 2003-04-16

Family

ID=26305745

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933488T Expired - Lifetime ES2184808T3 (en) 1994-10-05 1995-10-05 TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMELINIZING STATES USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE, THYROSINE OR TRIPTOPHAN AND OPTIONALLY A VITAMIN B12 COMPOSITE.

Country Status (19)

Country Link
US (2) US6096737A (en)
EP (1) EP0784476B1 (en)
JP (1) JPH10508583A (en)
AT (1) ATE227124T1 (en)
AU (1) AU710339B2 (en)
CA (1) CA2200761C (en)
CZ (1) CZ293873B6 (en)
DE (1) DE69528773T2 (en)
DK (1) DK0784476T3 (en)
ES (1) ES2184808T3 (en)
FI (1) FI116659B (en)
HU (1) HU225493B1 (en)
IS (1) IS1956B (en)
NO (1) NO314486B1 (en)
NZ (1) NZ293642A (en)
PL (1) PL181802B1 (en)
PT (1) PT784476E (en)
SK (1) SK281932B6 (en)
WO (1) WO1996011009A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335323B2 (en) * 1996-07-05 2002-01-01 The Wwk Trust Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin B12 and/or precursors or inducers of a neurotransmitter
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) * 1999-02-24 1999-04-21 Worsley Andrew P Composition for the treatment of pain
GB9906808D0 (en) * 1999-03-24 1999-05-19 Kilgowan Limited Formulation for treatment of pain
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
CA2774959C (en) 2000-08-04 2016-05-31 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) * 2002-03-14 2004-12-21 Duane Bennett Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
DK1571970T3 (en) 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnosis and monitoring of diseases
CA2514061A1 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
PT2537524T (en) * 2003-05-15 2016-09-05 Ampio Pharmaceuticals Inc Treatment of t-cell mediated diseases
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
US20050192261A1 (en) * 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
US20110136742A1 (en) * 2006-02-24 2011-06-09 Travis Mickle Antidepressant prodrugs
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp Treatment of diseases
EP2765968A4 (en) 2011-10-10 2015-01-21 Ampio Pharmaceuticals Inc Implantable medical devices with increased immune tolerance, and methods for making and implanting
MY167804A (en) 2011-10-10 2018-09-26 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
JP6231484B2 (en) 2011-10-28 2017-11-15 アンピオ ファーマシューティカルズ，インコーポレイテッド Rhinitis treatment
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6723222B2 (en) 2014-08-18 2020-07-15 アンピオ ファーマシューティカルズ，インコーポレイテッド Treatment of joint pathology
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
GB2544630A (en) 2015-11-19 2017-05-24 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
CA3041358A1 (en) * 2016-10-25 2018-05-03 Uti Limited Partnership Treatment for progressive multiple sclerosis
US11723945B2 (en) 2017-04-25 2023-08-15 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (en) * 2017-07-18 2019-01-23 Centre National De La Recherche Scientifique Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497306A (en) * 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4409243A (en) * 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
DE3519687A1 (en) * 1985-06-01 1986-12-04 Veit Arend Pharmaceutical containing amino acids
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (en) * 1992-02-12 1998-09-24 Kragler Peter Medicines for the treatment and / or prophylaxis of AIDS and other related diseases

Also Published As

Publication number Publication date
NZ293642A (en) 1998-10-28
SK43897A3 (en) 1998-08-05
PL319830A1 (en) 1997-09-01
CZ293873B6 (en) 2004-08-18
HU225493B1 (en) 2007-01-29
IS1956B (en) 2004-11-15
DE69528773T2 (en) 2003-09-04
AU3612695A (en) 1996-05-02
CA2200761C (en) 2008-02-26
US6096737A (en) 2000-08-01
DK0784476T3 (en) 2003-03-17
NO971539L (en) 1997-04-04
FI116659B (en) 2006-01-31
US6569850B1 (en) 2003-05-27
SK281932B6 (en) 2001-09-11
AU710339B2 (en) 1999-09-16
PL181802B1 (en) 2001-09-28
DE69528773D1 (en) 2002-12-12
EP0784476A1 (en) 1997-07-23
CA2200761A1 (en) 1996-04-18
WO1996011009A1 (en) 1996-04-18
FI971290A0 (en) 1997-03-26
FI971290A (en) 1997-06-02
IS4454A (en) 1997-03-26
JPH10508583A (en) 1998-08-25
NO971539D0 (en) 1997-04-04
EP0784476B1 (en) 2002-11-06
PT784476E (en) 2003-03-31
ATE227124T1 (en) 2002-11-15
NO314486B1 (en) 2003-03-31
CZ99597A3 (en) 1997-11-12
HUT77380A (en) 1998-04-28

Similar Documents

Publication Publication Date Title
ES2184808T3 (en) TREATMENT OF MULTIPLE SCLEROSIS (MS) AND OTHER DEMELINIZING STATES USING LOFEPRAMINE IN COMBINATION WITH L-PHENYLALANINE, THYROSINE OR TRIPTOPHAN AND OPTIONALLY A VITAMIN B12 COMPOSITE.
EP0687175A4 (en) Method for treating emotional or mental illness and emotional or mental illness concomitant with seizures
UA32429C2 (en) Agent for treatment of patient with enuresis
BR9610838A (en) Process for treating an individual having a pathological condition involving neovascularization.
ATE235901T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING 3-(2,2,2-TRIMETHYLHYDRAZINIUM)PROPRIONATE AND GAMMA-BUTYROBETAIN FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
BR0307022A (en) Method of treating a patient who needs analgesia
ES2175437T3 (en) COMPOSITION OF ENALAPRIL AND LOSARTAN.
NO984197L (en) Procedure for treating autism
PL329219A1 (en) Application of benzonaphtene derivatives in production of drugs for treating nervous system diseases
TR199801801T2 (en) Treatment of substance abuse.
KR960003741A (en) Osteoblast proliferation factor
ES2183977T3 (en) COMBINATION OF TEMOZOLOMIDE AND ALFA-INTERFERON FOR THE TREATMENT OF ADVANCED CANCER.
EA199800820A1 (en) METHOD OF TREATING ABUSE OF MEDICINES
EA199800818A1 (en) Method of treating insomnia
CO4700451A1 (en) N, N-DIETHYL-8 DIMALEATE, 8-DIPROPIL-2-AZASPIRO [4.5] DECANE-2-PROPANAMINE
UA10254A (en) Method for treating diabetes mellitus
UA32580C2 (en) Drug for treatment of paralytic intestinal obstructioni
UA29025A (en) The method for treatment of endocrine infertility
UA30659A (en) Method for reduction of drug dependence
MD950121A (en) Method for treatment of ischeme insults consequences
MX9704887A (en) Pharmaceutical compositions for the treatment of depressive disorders.
RU94033502A (en) Method for treating children suffering from secondary pancreatitis